Table 1.
Baseline characteristics of patients.
| Variables | Deveriation set (n=530) | Validation set (n=123) |
|---|---|---|
| Age, mean ± SD | 57.2±10.7 | 58.2±11.1 |
| Gender, n (%) | ||
| Male | 256(48.3%) | 71(57.7%) |
| Female | 274(51.7%) | 52(42.3%) |
| Cirrhosis, n (%) | 148(27.9%) | 16(13.0%) |
| Ascite, n (%) | 50(9.4%) | 60(48.8%) |
| Child score, n (%) | ||
| 5 | 451(85.1%) | 93(75.6%) |
| 6 | 79(14.9%) | 30(24.4%) |
| Multiple tumors, n (%) | 157(29.6%) | 36(29.3%) |
| Tumor size (cm), mean ± SD | 5.9±2.7 | 6.2±1.4 |
| Poor tumor differentiation, n (%) | 336(63.4%) | 90(73.2%) |
| Hepatolithiasis, n (%) | 88(16.6%) | 23(18.7%) |
| Microvascular invasion, n (%) | 53(10.0%) | 15(12.1%) |
| Macrovascular invasion, n (%) | 123(23.2%) | 25(20.3%) |
| Lymph node metastasis, n (%) | 129(24.3%) | 35(28.5%) |
| Biliary invasion, n (%) | 53(10.0%) | 63(51.2%) |
| Perineural invasion, n (%) | 77(14.5%) | 29(23.6%) |
| Liver capsule invasion | 325(61.3%) | 65(52.8%) |
| CA19-9, n (%) | ||
| ≥22U/ml | 138(26.0%) | 30(24.4%) |
| <22U/ml | 346(65.3%) | 93(75.6%) |
| Not available | 46(8.7%) | 0(0%) |
| HBsAg (positive),n(%) | 153(28.9%) | 22(17.9%) |
| HCV, n (%) | 3(0.6%) | 0(0%) |
| TNM stage, n (%) | ||
| I-II | 173(32.6%) | 45(36.6%) |
| III-IV | 357(67.4%) | 78(63.4%) |
| BCLC stage | ||
| 0-A | 268(50.6%) | 47(38.2%) |
| B-C | 262(49.4%) | 76(61.8%) |
| INR grade | ||
| <1.1 | 457(86.2%) | 80(65.0%) |
| ≥1.1 | 73(13.8%) | 43(35.0%) |
| GPR grade | ||
| <0.7 | 354(66.8%) | 55(44.7%) |
| ≥0.7 | 176(33.2%) | 68(55.3%) |
| Overall survival, month, mean ± SD | 24.9±21.4 | 26.2±20.8 |
CA19-9, cancer antigen 19-9; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; BCLC stage, Barcelona Clinic Liver Cancer stage; INR, international normalized ratio; GPR, gamma-glutamyl transpeptidase to platelet ratio.